In addition to its roles in cancer, LSD1 inhibition has also been postulated in neurodegenerative disorders (in particular, Alzheimer's), where LSD1 has been implicated in neuroinflammation, autophagy, the balance of neurotransmitters, and the progression of the tauopathy phenotype (reviewed in145). This evidence concerns the gene KDM1A and cancer.